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Abstract
Background: Malignant gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors
originating in the wall of the gastrointestinal tract. Myogenic gastrointestinal stromal tumor, a
distinctive morphologic variant is characterized by an unusually prominent myxoid stromal
background.
Case presentation: We report a case of myxoid variant of GIST in a 42 years old woman
presenting as an epigastric mass associated to an ovarian cyst and elevated CA-125. Histologically,
the lesions was composed of a proliferation of spindle cells in an abundant myxoid stroma, without
evidence of atypia or anaplasia. Immunohistochemical stains showed strong positive staining with
muscle actin, positive staining with CD34 and weak positive staining with CD117, while showed
negative for S-100.
Conclusion: At surgery every effort should be made to identify the origin of the tumor. A
complete surgical removal of the tumor should be obtained, as this is the only established
treatment that offers long term survival.
Background
Gastrointestinal stromal tumors (GIST) are rare tumors
that may arise anywhere in the tubular gastrointestinal
tract, but stomach is the most common site of localiza-
tion. Surgery is the main stay of treatment and complete
resection is achieved in most of cases [1]. The 5 year over-
all survival ranges from 21% to 88% in different series,
depending from risk grading and completeness of surgical
resection [1-4]. In light of the tendency of these tumors to
pursue an indolent clinical course with a significant risk of
late relapse, a brisk follow-up is advocated for all patients
[5]. Imatinib mesylate is proposed as therapy for high risk
GISTs after surgery [6]. A distinctive morphologic variant
of gastrointestinal stromal tumor has been described,
characterized by a prominent myxoid stromal back-
ground reminiscent of a neural neoplasm but lacking the
immunohistochemical or ultrastructural features of
peripheral nerve sheath or ganglionic differentiation. This
variant is more frequent in women and mostly occurs in
the stomach. These lesions are described grossly as well
circumscribed, unencapsulated, with a prominently
myxoid and often cystic cut surface [7]. We report a case
of myxoid variant GIST, occurring in a 42 year old
woman.
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Case presentation
A 42-year-old woman presented with pelvic pain, palpa-
ble pelvic mass extended to the epigastric region, and ele-
vated CA-125 (61.8 U/ml). Computed tomography (CT)
imaging showed a left 6 × 5 cm cystic ovarian lesion and
a 12 × 9.5 cm solid mass in the epigastric region (figure 1,
2). A preoperative diagnosis of metastatic ovarian malig-
nancy or FIGO stage III ovarian malignancy was made. At
laparotomy, a left ovarian cyst was seen along with a solid
mass attached to the greater curvature of stomach which
was easily dissected from it. Histologically, the lesions was
composed of a proliferation of spindle cells embedded in
an abundant myxoid stroma, without evidence of frank
atypia or anaplasia. Histochemical stains showed strong
positive staining with muscle actin, positive staining with
CD34 and weak positive staining with CD117, while it
was negative for S-100. The histological work up was con-
clusive for a low malignancy GIST – myxoid variant, being
the mass volume the only risk factor [3,5], the ovarian
mass on the other hand was a follicular cyst. Due to the
lack of clear risk factors for recurrence, and to complete
surgical tumor resection, the patient was advised follow-
up only.
Discussion
Fletcher et al., [5] classified these tumors in to very low,
low, intermediate and high risk, categories according to
tumor size and mitotic count. Tumors <2 cm and mitotic
count <5/50 high power field (HPF) were categorized as
very low risk; tumor size 2–5 cm and mitotic count <5/50
HPF as low risk; tumor size <5 cm and mitotic count 6–
10/50 HPF or tumor size 5–10 cm and mitotic count <5/
50 HPF as intermediate risk; tumor size >5 cm and mitotic
count >5/50 HPF or tumor size >10 cm and any mitotic
rate or tumor any size and mitotic rate >10/50 HPF as
high risk. As reported by others [8-10], GIST may mimic a
pelvic masses. In such circumstances they are first noticed
by gynecologists and are often diagnosed, prior to surgery,
as ovarian tumors, either as metastatic from, or metasta-
tizing to gastrointestinal tract. Only at surgery their nature
is fully understood. The same was true in our case as a
solid epigastric mass was associated to an ovarian cystic
lesion similar to that in Krukenberg tumor. Therefore, in
presence of a pelvic mass, especially if other unusual signs
are present, the possibility of other than a gynecologic
tumor has to be considered. At surgery, every effort should
be made to identify the origin of the tumor and related
anatomic structures. In the case of GIST, a complete surgi-
cal removal of the tumor should be obtained, as despite
significant advances in new chemotherapic regimens have
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Computed tomography imaging of upper abdomen showing  solid mass lesion in epigastric area Figure 1
Computed tomography imaging of upper abdomen showing 
solid mass lesion in epigastric area.
Computed tomography imaging of the pelvis showing cystic  ovarian lesion Figure 2
Computed tomography imaging of the pelvis showing cystic 
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